MGNX - Zai Lab Recent GIST Hype And HER2 Turmoil Revealed An Excellent Short-Selling Opportunity
Zai Lab is a Chinese biotech company mainly focuses on oncology. It licenses in innovative drugs and medical devices from various US partners and tries to get CFDA approval and commercialization in China. Examples of such pipelines are niraparib from GSK (previously Tesaro), Optune from Novocure and Margetuximab from MacroGenics. All these partners are US-listed, which makes information quite transparent.
GSK’s niraparib, commercialized as Zejula, is a PARP (Poly ADP Ribose Polymerase) inhibitor. PARP protein repairs DNA breaks and plays an important role in fixing DNA damage during mitosis. Cancer cells divide vigorously and easily